Nanobodies - From llamas to therapeutic proteins

Drug Discovery Today: Technologies

Volumn 7, Issue 2, 2010, Pages

  Kolkman, Joost A ^a   Law, Debbie A ^a  

^a ABLYNX NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CATUMAXOMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; CLOTINAB; EPITOPE; HEXAMETAPHOSPHATE SODIUM; MONOCLONAL ANTIBODY; NANOBODY; OKT 3; PANITUMUMAB; RANIBIZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; VARIANT SURFACE GLYCOPROTEIN;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN BINDING; ASCITES; CAMEL; CANCER IMMUNOTHERAPY; CHIMERA; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; LLAMAS; MALIGNANT ASCITES; MOLECULAR WEIGHT; NONHUMAN; PH; PROTEIN DENATURATION; PROTEIN DOMAIN; REVIEW; SOLID TUMOR; THERMOSTABILITY;

EID: 78149343713     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2010.03.002     Document Type: Review

References (26)

1. C. Hamers-Casterman Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448
2. J. Davies, and L. Riechmann Camelising human antibody fragments: NMR studies on VH domains FEBS Lett. 339 1994 285 290
3. K.E. Conrath Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs J. Biol. Chem. 276 2001 7346 7350
4. E. De Genst Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies Proc. Natl. Acad. Sci. U. S. A. 103 2006 4586 4591
5. B. Stijlemans Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm J. Biol. Chem. 279 2004 1256 1261
6. L.G.J. Frenken Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae J. Biotechnol. 78 2000 11 21
7. F. Rahbarizadeh Overexpression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris Mol. Immunol. 43 2006 426 435
8. M.M. Harmsen, and H.J. De Haard Properties, production and applications of camelid single-domain antibody fragments Appl. Microbiol. Biotechnol. 77 2007 13 22
9. C. Kruger Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries Appl. Microbiol. Biotechnol. 72 2006 732 737
10. J.M. Van der Vaart Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments Vaccine 24 2006 4130 4137
11. K. Vandenbroucke Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis Mucosal Immunol. 3 2010 49 56
12. M.M. Harmsen Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy Appl. Microbiol. Biotechnol. 72 2006 544 551
13. M. Dumoulin Single-domain antibody fragments with high conformational stability Protein Sci. 11 2002 500 515
14. R.H. Van der Linden Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies Biochim. Biophys. Acta 1431 1999 37 46
15. H. Revets Nanobodies as novel agents for cancer therapy Expert Opin. Biol. Ther. 5 2005 111 124
16. S. Ewert Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains Biochemistry 41 2002 3628 3636
17. J.M. Perez Thermal unfolding of a llama antibody fragment: a two-state reversible process Biochemistry 40 2001 74 83
18. D. Gueorguieva Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis FASEB J. 20 2006 2636 2638
19. B. Serruys Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice Hepatology 49 2008 39 49
20. K. McGonigal Isolation and functional characterization of single domain antibody modulators of Caspase-3 and apoptosis Appl. Microbiol. Biotechnol. 157 2009 226 236
21. P. Verheesen Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody Hum. Mol. Genet. 15 2006 105 111
22. R.A. Beckman Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors Cancer 109 2007 170 179
23. G.P. Adams High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules Cancer Res. 61 2001 4750 4755
24. G.P. Adams Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu Br. J. Cancer 77 1998 1405 1412
25. I. Verel Tumor targeting of antibodies with different affinity for target antigen CD44V6 in nude mice bearing head and neck cancer xenografts Int. J. Cancer 99 2002 396 402
26. B.M. Tijink Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology Mol. Cancer Ther. 7 2008 2288 2297